Answers are grounded in this paper and cite their sources.
Immunoglobulin G4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder with a high rate of disease relapse, contributing to fibrosis, organ damage, and cumulative treatment burden. Relapse in IgG4-RD can occur either in previously affected organs or as de novo organ involvement. Recent advances have shown that both innate and adaptive immune responses contribute to disease persistence and relapse. Regarding risk factors, multiple clinical and serological characteristics as well as treatment-related factors have been associated with disease relapse. Therapeutic strategies have consequently evolved from remission induction alone toward relapse prevention and long-term disease control. Maintenance glucocorticoids, conventional immunosuppressive agents, rituximab, and emerging targeted therapies have demonstrated varying degrees of efficacy in reducing recurrence. In this review, we summarize current evidence regarding relapse patterns, underlying mechanisms, risk factors, and therapeutic approaches in IgG4-RD, with the aim of improving relapse prediction and guiding personalized long-term management.
No takes yet. Share an insight, caveat, or question.
Ge et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: